Wedbush Has Negative Estimate for TSE:FRX FY2026 Earnings

Fennec Pharmaceuticals Inc. (TSE:FRX) – Stock analysts at Wedbush decreased their FY2026 earnings per share (EPS) estimates for shares of Fennec Pharmaceuticals in a note issued to investors on Monday, October 13th. Wedbush analyst D. Nierengarten now forecasts that the biopharmaceutical company will earn $0.62 per share for the year, down from their previous forecast of $0.76. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share.

Fennec Pharmaceuticals Price Performance

FRX stock opened at C$11.80 on Tuesday. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83. The company has a market capitalization of C$328.42 million, a PE ratio of -26.22 and a beta of 2.48. Fennec Pharmaceuticals has a 12-month low of C$5.65 and a 12-month high of C$13.83. The business’s fifty day moving average price is C$12.25 and its 200 day moving average price is C$10.78.

Insider Activity

In related news, insider Southpoint Capital Advisors Lp sold 20,609 shares of the business’s stock in a transaction on Thursday, October 9th. The stock was sold at an average price of C$12.89, for a total value of C$265,650.01. Following the sale, the insider owned 4,010,100 shares in the company, valued at approximately C$51,690,189. The trade was a 0.51% decrease in their position. In the last quarter, insiders sold 68,889 shares of company stock valued at $900,406. 16.20% of the stock is currently owned by insiders.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.